<table border="0" id="ie8e165ec-5e5b-4833-866e-8e5357f0cab7" width="100%" xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 9: Bioavailability of Divalproex Sodium Extended-Release Tablets Relative to Divalproex Sodium Delayed-Release Tablets When Divalproex Sodium Extended-Release Tablets Dose is 8 to 20% Higher</caption>
<tbody>
<tr>
<td>Study <br/>Population<br/>
<br/>
</td>
<td>Regimens<br/>
</td>
<td>   Relative </td>
<td>Bioavailability</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>
<br/>
</td>
<td>Divalproex Sodium Extended-Release Tablets <br/>vs.<br/>Divalproex Sodium Delayed-Release Tablets<br/>
<br/>
</td>
<td>AUC<sub>24</sub>
<br/>
</td>
<td>C<sub>max</sub>
<br/>
</td>
<td>C<sub>min</sub>
<br/>
</td>
</tr>
<tr>
<td>Healthy Volunteers (N=35)<br/>
</td>
<td>1000 and 1500 mgDivalproex sodium extended-release<br/> tablets vs<br/> 875 and 1250 mg Divalproex sodium delayed-release<br/> tablets<br/>
<br/>
</td>
<td>1.059<br/>
</td>
<td>0.882<br/>
</td>
<td>1.173<br/>
</td>
</tr>
<tr>
<td>Patients with epilepsy on concomitant <br/>enzyme-inducing antiepilepsy drugs <br/>(N = 64)<br/>
</td>
<td>1000 and 5000 mgDivalproex sodium extended-release<br/>
 tablets vs<br/>
 875 and 4250 mg Divalproex sodium delayed-release<br/>
 tablets</td>
<td>1.008<br/>
</td>
<td>0.899<br/>
</td>
<td>1.022<br/>
</td>
</tr>
</tbody>
</table>